

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

NCT07499700

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Bio-Thera Solutions
Enrollment	192 participants

Key Eligibility Criteria

Inclusion (2)

- Clinically diagnosed with NS, with a pathological diagnosis of Minimal change disease/Focal segmental glomerulosclerosis confirmed by renal biopsy within 7 years (Minimal change disease) or 10 years (Focal segmental glomerulosclerosis) prior to screening, and who are responsive to corticosteroid therapy
- The time since achieving complete remission following corticosteroid therapy for the most recent active or relapsed disease is within 8 weeks of baseline

Exclusion (9)

- Secondary Nephrotic Syndrome
- Known genetic defects associated with Nephrotic Syndrome or a family history of Nephrotic Syndrome
- Receipt of any B-cell depletion or B-cell-modifying therapy within 6 months prior to baseline
- History of allergy to monoclonal antibodies; or a predisposition to allergies
- Received treatment with immunosuppressants within 60 days prior to baseline

... and 4 more (see full listing online)

Locations (1 total)

Peking University First Hospital, Beijing, Beijing Municipality, China